The request is based on the totality of preclinical-, clinical-, and manufacturing-related data provided to the FDA, including the results of two large pivotal clinical trials that demonstrated an overall efficacy of approximately 90% and a reassuring safety profile, according to the company.

Novavax conducted two pivotal phase III clinical trials: Prevent-19, which comprised approximately 30,000 participants in the U.S. and Mexico, with results that were published in the New England Journal of Medicine (NEJM), and an additional trial of almost 15,000 participants in the U.K., which was also published in NEJM.

In both trials, NVX-CoV2373 demonstrated efficacy, with a reassuring safety profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups, said Novavax. The most common adverse reactions observed were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.

Novavax will continue to collect and analyze real-world data, including the monitoring of safety and the evaluation of variants as the vaccine is distributed in authorized markets. As part of the Prevent-19 trial, a booster study is ongoing to evaluate the safety and effectiveness of a third dose of the vaccine, as well as a study in adolescents ages 12 to 17.

NVX-CoV2373 has been granted conditional authorization by multiple regulatory agencies worldwide, including the European Commission. It has received an emergency use listing from the World Health Organization, with additional filings that are currently under review.

Novavax receives CMA from European Commission
Novavax announced that the European Commission has granted the company a conditional marketing authorization (CMA) for its Nuvaxovid COVID-19 vaccine...

Novavax completes submission of COVID vaccine candidate to WHO
Novavax has completed its rolling submission to the World Health Organization (WHO) for emergency use listing of NVX-CoV2373, its COVID-19 vaccine candidate.

Novavax submits COVID vaccine candidate to TGA
Novavax completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate in Australia.

Novavax COVID-19 vaccine booster appears effective after primary vaccination
Novavax announced preliminary data indicating that a single booster dose of the company's recombinant nanoparticle protein-based COVID-19 vaccine drew...

Novavax touts COVID-19 vaccine results
Novavax is highlighting study results that demonstrate the efficacy of its COVID-19 vaccine, NVX-CoV2373, as well as a new COVID-19 vaccine it is developing...